Posts tagged “Pozen”
Early-stage startups seeking money weren't the only companies taking the stage at CED's Tech Venture Conference. WRALTechWire Insiders can read all about six companies that have grown from upstarts to stalwarts in their respective sectors. Will Bronto, Netsertive, Overture, ReverbNation, StrikeIron and WebAssign someday go the IPO route?
Pozen believes that Sanofi is the best possible big pharma partner to sell its 'safer on the stomach' aspirin. Read how this drug will fits in Sanofi's drug portfolio.
While Pozen works on landing a drug partner to market its prospective new heart drug, it's now starting to look like Pozen might need global partners. Read more about the company's status.
AstraZeneca's decision to stop promoting arthritis drug Vimovo in key markets leaves drug partner Pozen figuring out its options for what is currently its top-selling product. What might the company do?
Shares plunged Wednesday after the Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen?
The Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen and its shareholders?
Sales of Vimovo, a pain reliever sold by partner AstraZeneca, surged in 2012, thus delivering a growing revenue stream to Chapel Hill-based Pozen. But the company still posted a $25 million dollar loss.
The Chapel Hill drug developer says the FDA wants more information on PA32540, an aspirin combination drug developed to deliver the cardiovascular benefits of aspirin in a way less likely to cause stomach irritation characteristic of aspirin alone.
- Mediterranean-inspired restaurant sets opening date in Glenwood South
- Bank stocks help Dow to another record; tech stocks recover
- Get used to it: Economists see 'new normal' of slow growth
- Trump's tariff plan hits a hurdle: Congressional Republicans
- US services firms grow at fastest pace since October 2015